文献速递瓣膜外科

50-70岁患者生物型与机械型主动脉瓣假体的长期临床结局

Long-term clinical outcomes in patients between the age of 50-70 years receiving biological versus mechanical aortic valve prostheses.
PubMed 文献 · Eur J Cardiothorac Surg · 2025-01-01

该研究纳入1996-2023年在本中心接受择期/急诊孤立主动脉瓣置换的50-70岁患者1708例,其中69.7%接受生物瓣。逆概率评分加权后短期结局无差异,但机械瓣组长期生存更优(P<0.001)。亚组分析显示19mm生物瓣长期生存最差,21mm机械瓣生存优于19mm、21mm和23mm生物瓣。严重患者-假体不匹配者生存率最低。

要点

  • 50-70岁患者机械瓣长期生存优于生物瓣(P<0.001)。
  • 19mm生物瓣长期生存最差,21mm机械瓣生存优于19/21/23mm生物瓣。
  • 严重患者-假体不匹配者生存率最低(HR 1.56)。

核心结论

  • 50-70岁接受机械主动脉瓣的患者长期生存优于生物瓣,提示需重新评估该年龄组的瓣膜选择策略。

研究设计与样本

  • 回顾性队列研究,纳入1996-2023年在本中心接受择期/急诊孤立主动脉瓣置换的50-70岁患者1708例(61%男性),中位年龄63.60岁(IQR 58.28-67.0),其中1191例(69.7%)接受生物瓣。

主要发现

  • 逆概率评分加权后,生物瓣与机械瓣组短期结局无差异。
  • 机械瓣组长期生存优于生物瓣组(P<0.001)。
  • 19mm生物瓣患者长期生存最差。
  • 21mm机械瓣生存优于19mm生物瓣(HR 0.25,95%CI 0.17-0.37,P<0.001)、21mm生物瓣(HR 0.33,95%CI 0.23-0.48,P<0.001)和23mm生物瓣(HR 0.40,95%CI 0.27-0.60,P<0.001)。
  • 严重患者-假体不匹配者生存率最低(HR 1.56,95%CI 1.21-2.00,P<0.001)。

临床怎么用

  • 对于50-70岁主动脉瓣置换患者,应充分考虑机械瓣在长期生存上的优势,尤其避免使用19mm生物瓣。
  • 术前应评估并尽量避免严重患者-假体不匹配,以改善长期生存。

局限性

  • 本研究为单中心回顾性研究,结论需多中心验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The last 2 decades have seen an incremental use of biological over mechanical prostheses. However, while short-term clinical outcomes are largely equivalent, there is still controversy about long-term outcomes. METHODS: All patients between the ages of 50 and 70 years undergoing elective/urgent isolated aortic valve replacement at our institute between 1996 and 2023 were included. Trends, early, and long-term outcomes were investigated. RESULTS: A total of 1708 (61% male) patients with a median age of 63.60 (interquartile range: 58.28-67.0) years were included of which 1191 (69.7%) received a biological prosthesis. After inverse propensity score weighting, there were no short-term differences when comparing patients receiving biological and mechanical valves. However, patients who received mechanical prostheses had better long-term survival (P < 0.001). Sub-group analysis revealed that patients with biological size 19 mm prosthesis had the worst long-term survival. Patients with a size 21-mm mechanical prosthesis had better survival compared to both size 19-mm [hazard ratio (HR) 0.25, 95% confidence interval (CI) 0.17-0.37, P < 0.001], 21-mm (HR 0.33, 95% CI 0.23-0.48, P < 0.001) and 23-mm (HR 0.40, 95% CI 0.27-0.60, P < 0.001) biological prosthesis. Additionally, patients with severe patient-prosthesis mismatch exhibited the lowest survival rate compared to those with moderate or no (HR 1.56, 95% CI 1.21-2.00, P < 0.001). CONCLUSIONS: Patients aged between 50 and 70 years with a mechanical aortic prosthesis had better long-term survival compared to those with a biological prosthesis. Our study underscores the need for a critical re-evaluation of prosthesis selection strategies in this age group.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Chan J, Narayan P, Fudulu DP, et al. Long-term clinical outcomes in patients between the age of 50-70 years receiving biological versus mechanical aortic valve prostheses. Eur J Cardiothorac Surg. 2025. PMID: 39891404. doi:10.1093/ejcts/ezaf033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。